Last reviewed · How we verify
UIC201602 and co-administration of UIC201601 and UIC201602
UIC201602 and co-administration of UIC201601 and UIC201602 is a Small molecule drug developed by Korea United Pharm. Inc.. It is currently in Phase 1 development.
At a glance
| Generic name | UIC201602 and co-administration of UIC201601 and UIC201602 |
|---|---|
| Sponsor | Korea United Pharm. Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- UIC201602 and co-administration of UIC201601 and UIC201602 CI brief — competitive landscape report
- UIC201602 and co-administration of UIC201601 and UIC201602 updates RSS · CI watch RSS
- Korea United Pharm. Inc. portfolio CI
Frequently asked questions about UIC201602 and co-administration of UIC201601 and UIC201602
What is UIC201602 and co-administration of UIC201601 and UIC201602?
UIC201602 and co-administration of UIC201601 and UIC201602 is a Small molecule drug developed by Korea United Pharm. Inc..
Who makes UIC201602 and co-administration of UIC201601 and UIC201602?
UIC201602 and co-administration of UIC201601 and UIC201602 is developed by Korea United Pharm. Inc. (see full Korea United Pharm. Inc. pipeline at /company/korea-united-pharm-inc).
What development phase is UIC201602 and co-administration of UIC201601 and UIC201602 in?
UIC201602 and co-administration of UIC201601 and UIC201602 is in Phase 1.